AIM Vaccine Co., Ltd.
Quick facts
Phase 3 pipeline
- LVRNA009 · Immunology/Oncology
LVRNA009 is an mRNA vaccine designed to stimulate immune responses against specific disease targets through encoded antigen expression.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about AIM Vaccine Co., Ltd.
What is AIM Vaccine Co., Ltd.'s pipeline?
AIM Vaccine Co., Ltd. has 1 drugs in Phase 3, 1 in Phase 2, 2 in Phase 1. Late-stage candidates include LVRNA009.
Related
- Sector hub: All tracked pharma companies